Related Experiment Video
Updated: May 9, 2026
Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry
Published on: November 14, 2025
Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients
Mi Li1, Xiubin Xiao, Lianqing Liu
1State Key Laboratory of Robotics, Shenyang Institute of Automation, Chinese Academy of Sciences, Shenyang 110016, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Abstract:
CD20, a membrane protein highly expressed on most B-cell lymphomas, is an effective target demonstrated in clinical practice for treating B-cell non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. In this work, we applied atomic force microscopy (AFM) to map the nanoscale distribution of CD20 molecules on the surface of cancer cells from clinical B-cell NHL patients under the assistance of ROR1 fluorescence recognition (ROR1 is a specific cell surface marker exclusively expressed on cancer cells). First, the ROR1 fluorescence labeling experiments showed that ROR1 was expressed on cancer cells from B-cell lymphoma patients, but not on normal cells from healthy volunteers. Next, under the guidance of ROR1 fluorescence, the rituximab-conjugated AFM tips were moved to cancer cells to image the cellular morphologies and detect the CD20-rituximab interactions on the cell surfaces. The distribution maps of CD20 on cancer cells were constructed by obtaining arrays of (16×16) force curves in local areas (500 × 500 nm(2)) on the cell surfaces. The experimental results provide a new approach to directly investigate the nanoscale distribution of target protein on single clinical cancer cells.
Insights
Researchers used atomic force microscopy to map CD20 protein distribution on B-cell lymphoma cells. This technique, guided by ROR1 fluorescence, visualizes CD20-rituximab interactions on single cancer cells for potential therapeutic insights.
Area of Science:
- Biophysics
- Nanotechnology
- Oncology
Background:
- CD20 is a key therapeutic target in B-cell non-Hodgkin's lymphoma (NHL).
- Rituximab, an anti-CD20 monoclonal antibody, is clinically effective against NHL.
- Understanding CD20 nanoscale distribution is crucial for optimizing targeted therapies.
Purpose of the Study:
- To develop and apply a novel AFM-based method for mapping CD20 distribution on clinical B-cell lymphoma cells.
- To visualize CD20-rituximab interactions at the nanoscale on single cancer cells.
- To utilize ROR1 as a specific cancer cell marker for targeted imaging.
Main Methods:
- Atomic Force Microscopy (AFM) with rituximab-conjugated tips.
- ROR1 fluorescence recognition for cancer cell identification.
- Acquisition of nanoscale force curve arrays (16x16) on cell surfaces (500x500 nm²).
Main Results:
- ROR1 was confirmed as a specific marker for B-cell lymphoma cancer cells, absent in healthy cells.
- AFM successfully imaged cellular morphology and detected CD20-rituximab interactions.
- Nanoscale distribution maps of CD20 on single clinical cancer cells were generated.
Conclusions:
- This study presents a new approach to directly investigate nanoscale target protein distribution on individual clinical cancer cells.
- The ROR1-guided AFM method offers high-resolution insights into CD20 localization relevant to rituximab therapy.
- This technique has potential for advancing personalized cancer treatment strategies.
